

Abbexa Ltd, Innovation Centre, Cambridge Science Park, Cambridge, CB4 0EY, UK
Telephone: +44 (0) 1223 755950 - Fax: +44 (0) 1223 755951 - E-Mail: info@abbexa.com

SNX13 siRNA

Catalogue No.: abx934592

siRNA to inhibit SNX13 expression using RNA interference.

This product is provided as two 5 nmol vials (10 nmol), three 5 nmol vials (15 nmol) or 2x three 5 nmol vials (30 nmol) of lyophilized siRNA oligo duplexes. Each vial contains slightly different sequences to ensure full knockout of the gene. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. The siRNA oligos are also chemically modified (2'-OMe) for increased stability and enhanced knockdown in vitro and in vivo.

Target: SNX13

Reactivity: Human

Host: Synthetic

Tested Applications: RNAi

Purity: > 97%

Form: Lyophilized

Specificity: SNX13 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.

Storage: Shipped at 4 °C. Store at -20 °C for up to one year.

Swiss Prot: [Q9Y5W8](#)

GeneID: [23161](#)

Gene Symbol: SNX13

Directions for use:

1. Transfect with 100 nM siRNA 48 to 72 hours prior to cell lysis.
2. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube.
3. Resuspend the siRNA oligos to an appropriate concentration with DEPC water.

Each vial is suitable for 250 transfections in a 24 well plate (20 pmol for each well).

Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.

Note: This product is for research use only.